^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
tagitanlimab (HBM9167)
i
Other names: HBM9167, A 167, KL A167, KLA167, A167, KL-A167
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Harbour BioMed, Sichuan Kelun Pharma
Drug class:
PD-L1 inhibitor
Related drugs:
5ms
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
P2, N=110, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
|
cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
6ms
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma (clinicaltrials.gov)
P2, N=109, Completed, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Unknown status --> Completed
Trial completion
|
tagitanlimab (HBM9167)
6ms
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
P3, N=295, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
cisplatin • gemcitabine • tagitanlimab (HBM9167)
6ms
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (clinicaltrials.gov)
P2, N=175, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | N=95 --> 175 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
2years
A Phase Ⅱ Clinical Study of Combination Therapy of SKB264 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
P2, N=110, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
New P2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • EGFR wild-type • ALK fusion • ALK negative
|
cisplatin • carboplatin • sacituzumab tirumotecan (MK-2870) • tagitanlimab (HBM9167)
Share via
